Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Acquire Biolab for $120M

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has signed a deal to acquire Australian analytical instruments and life science consumables provider Biolab for A$175 million (US $120 million).

Biolab is a division of publicly traded Australian firm Alesco Corp. and has annual revenues of around A$170 million. Thermo Fisher said that it expects to close the transaction on April 30, and that it will integrate the company in to its Laboratory Products and Services Segment.

Marijn Dekkers, president and CEO of Thermo Fisher, said in a statement that the acquisition will significantly strengthen the firm's presence in the Australia, New Zealand, and South Pacific markets.

Among the products that Biolab distributes are chromatography, molecular spectroscopy, molecular imaging, and proteomic and genomic analytical instruments. It also sells diagnostic kits and sample preparation products, among its other offerings.

There had been ongoing speculation recently about a possible acquisition coming from Thermo Fisher. Two weeks ago, Leerink Swann analyst Isaac Ro said in a research note that possible targets could be in the areas of bioprocess tools, HPLC, or diagnostics.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.